[Ranibizumab, bevacizumab and aflibercept for age-related macular degeneration]
Mengarelli C, Augustovski, Pichon-Riviere A, García Martí S, Alcaraz A, Bardach A, Ciapponi A, López A, Rey-Ares L
Record ID 32015000863
Spanish
Authors' objectives:
To assess the evidence available on the efficacy, safety and issues related with coverage policies for the use of ranibizumab, bevacizumab and aflibercept in age-related macular degeneration.
Authors' recommendations:
There is high-quality evidence showing that angiogenesis inhibitors (ranibizumab, bevacizumab and aflibercept) improve visual acuity as well as the morphological changes in age-related macular degeneration. In the case of bevacizumab, despite not approved by the regulatory agencies, its off-label indication is supported by the evidence and widely used due to its similar effect and lower cost. It is also supported by different scientific societies and health sponsors.
Details
Project Status:
Completed
Year Published:
2015
URL for published report:
www.iecs.org.ar/home-ets/
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Argentina
MeSH Terms
- Intravitreal Injections
- Receptors, Vascular Endothelial Growth Factor
- Vascular Endothelial Growth Factor A
- Angiogenesis Inhibitors
- Wet Macular Degeneration
- Macular Degeneration
Contact
Organisation Name:
Institute for Clinical Effectiveness and Health Policy
Contact Address:
Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name:
info@iecs.org.ar
Contact Email:
info@iecs.org.ar
Copyright:
Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.